179 related articles for article (PubMed ID: 9210684)
41. Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis.
Thompson GR; Lewis JS; Nix DE; Patterson TF
Med Mycol; 2019 Feb; 57(Supplement_1):S76-S84. PubMed ID: 30690601
[TBL] [Abstract][Full Text] [Related]
42. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.
Barchiesi F; Di Francesco LF; Compagnucci P; Arzeni D; Giacometti A; Scalise G
J Antimicrob Chemother; 1998 Jan; 41(1):59-65. PubMed ID: 9511038
[TBL] [Abstract][Full Text] [Related]
43. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis.
Hoeprich PD; Merry JM
Eur J Clin Microbiol; 1985 Aug; 4(4):400-3. PubMed ID: 4043057
[TBL] [Abstract][Full Text] [Related]
44. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
45. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
Ryder NS; Leitner I
Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice.
Kamberi P; Atsuro H; Takayoshi T; Masaru N
Chemotherapy; 1998; 44(1):55-62. PubMed ID: 9444410
[TBL] [Abstract][Full Text] [Related]
47. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
Ramos G; Cuenca-Estrella M; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Aug; 44(2):283-6. PubMed ID: 10473237
[TBL] [Abstract][Full Text] [Related]
48. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.
Yotsuji A; Shimizu K; Araki H; Fujimaki K; Nishida N; Hori R; Annen N; Yamamoto S; Hayakawa H; Imaizumi H; Watanbe Y; Narita H
Antimicrob Agents Chemother; 1997 Jan; 41(1):30-4. PubMed ID: 8980750
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and in vitro antifungal activity of isoniazid-derived hydrazones against Coccidioides posadasii.
Cordeiro Rde A; de Melo CV; Marques FJ; Serpa R; Evangelista AJ; Caetano EP; Mafezoli J; de Oliveira Mda C; da Silva MR; Bandeira Tde J; Moreira JL; Brilhante RS; Rocha MF; Sidrim JJ
Microb Pathog; 2016 Sep; 98():1-5. PubMed ID: 27334293
[TBL] [Abstract][Full Text] [Related]
50. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
Gupta AK; Kohli Y; Batra R
Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561
[TBL] [Abstract][Full Text] [Related]
51. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
52. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.
Fung-Tomc JC; White TC; Minassian B; Huczko E; Bonner DP
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):163-7. PubMed ID: 10579098
[TBL] [Abstract][Full Text] [Related]
53. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
54. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
55. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
56. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans.
Burgess DS; Hastings RW; Summers KK; Hardin TC; Rinaldi MG
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):13-8. PubMed ID: 10744363
[TBL] [Abstract][Full Text] [Related]
57. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
58. Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
Kamberi P; Sobel RA; Clemons KV; Waldvogel A; Striebel JM; Williams PL; Stevens DA
Antimicrob Agents Chemother; 2007 Mar; 51(3):998-1003. PubMed ID: 17178793
[TBL] [Abstract][Full Text] [Related]
59. Therapy of systemic histoplasmosis in immunosuppressed mice with the triazole D0870.
Clemons KV; Martinez M; Homola ME; Stevens DA
J Med Vet Mycol; 1996; 34(4):241-6. PubMed ID: 8873882
[TBL] [Abstract][Full Text] [Related]
60. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
